Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02540226 · ClinicalTrials.gov registry record · Phase 4
Effect of Topical and Intravenous Tranexamic Acid (TXA) on Thrombogenic Markers in Patients Undergoing Knee Replacement
A Phase 4 study, sponsored by Hospital for Special Surgery, New York.
- Completed
- Registry status
- Phase 4
- Development phase
- 76
- Enrollment target
NCT02540226 is a Phase 4 study that has completed, run by Hospital for Special Surgery, New York. The registered enrollment target is 76 participants.
The verdict
NCT02540226, a Phase 4 study, has completed, sponsored by Hospital for Special Surgery, New York.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 76 participants
- Enrollment target
Study Summary
Tranexamic acid (TXA) is a drug that is being used more frequently at the Hospital for Special Surgery to lessen the amount of blood loss after total knee replacement (TKR). It is an anti-fibrinolytic agent, which means that it promotes the formation of blood clots. TXA can be given either intravenously or topically (placed directly on the open wound) before wound closure. Patients with certain medical conditions have been found to have a high risk of thrombosis after being given intravenous TXA, which may lead to serious complications. However, to date, no high-risk patients have been identified for use of topical TXA. This study will look at thrombogenic markers (proteins found in blood that promote clot formation) after TXA is given either intravenously or topically. If the effect on these markers is similar between intravenous and topical use of TXA, then the safety of topical TXA should be questioned. Of note, these markers have never been measured after TXA has been given topically. As a result, this information would be important for the medical community.
Interventions
- DRUG Topical saline
- DRUG Intravenous tranexamic acid
- DRUG Topical tranexamic acid
- DRUG Intravenous saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2015-11-19 |
| Est. Completion | 2019-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02540226
The ClinicalTrials.gov registry entry for NCT02540226 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hospital for Special Surgery, New York, which has 194 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Topical saline is the first listed.
NCT02540226 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02540226 about?
NCT02540226 is a clinical study titled "Effect of Topical and Intravenous Tranexamic Acid (TXA) on Thrombogenic Markers in Patients Undergoing Knee Replacement". Tranexamic acid (TXA) is a drug that is being used more frequently at the Hospital for Special Surgery to lessen the amount of blood loss after total knee replacement (TKR). It is an anti-fibrinolytic agent, which means that it promotes the formation of blood clots. TXA can be given either intraveno...
What is the current status of trial NCT02540226?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 76 participants. The study started on 2015-11-19. Estimated completion is 2019-12.
What interventions are being tested in trial NCT02540226?
The interventions under investigation include: Topical saline (DRUG), Intravenous tranexamic acid (DRUG), Topical tranexamic acid (DRUG), Intravenous saline (DRUG).
Who is sponsoring clinical trial NCT02540226?
This trial is sponsored by Hospital for Special Surgery, New York, which has 194 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.